ERAP1: a potential therapeutic target for a myriad of diseases
- 15 April 2020
- journal article
- review article
- Published by Informa UK Limited in Emerging Therapeutic Targets
- Vol. 24 (6), 535-544
- https://doi.org/10.1080/14728222.2020.1751821
Abstract
Introduction: Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) is a key regulator of the peptide repertoire displayed by Major Histocompatibility Complex I (MHC I) to circulating CD8+ T cells and NK cells. Studies have highlighted the essential requirement for the generation of stable peptide MHC I in regulating both innate and adaptive immune responses in health and disease. Areas covered: We review the role of ERAP1 in peptide trimming of N-terminally extended precursors that enter the ER, before loading on to MHC I, and the consequence of loss or downregulation of this activity. Polymorphisms in ERAP1 form multiple combinations (allotypes) within the population, and we discuss the contribution of this ERAP1 variation, and expression, on disease pathogenesis, including the resulting effect on both innate and adaptive immunity. We consider the current efforts to design inhibitors based on approaches using rational design and small molecule screening, and the potential effect of pharmacological modulation on the treatment of autoimmunity and cancer. Expert Opinion: ERAP1 is fundamental for the regulation of immune responses, through generation of the presented peptide repertoire at the cell surface. Modulation of ERAP1 function, through design of inhibitors, may serve as a vital tool for changing immune responses in disease.Keywords
Funding Information
- Cancer Research UK Programme Grant A16997 awarded to E James (A1997)
This publication has 86 references indexed in Scilit:
- Endoplasmic Reticulum Aminopeptidase-1 Functions Regulate Key Aspects of the Innate Immune ResponsePLOS ONE, 2013
- Structural insights into the molecular ruler mechanism of the endoplasmic reticulum aminopeptidase ERAP1Scientific Reports, 2011
- Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimmingProceedings of the National Academy of Sciences of the United States of America, 2011
- Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1Nature Structural & Molecular Biology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Balancing Selection Maintains a Form of ERAP2 that Undergoes Nonsense-Mediated Decay and Affects Antigen PresentationPLoS Genetics, 2010
- Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing Defines the Composition and Structure of MHC Class I Peptide Repertoire in Normal and Virus-Infected CellsPublished by The American Association of Immunologists ,2010
- Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinomaCancer Immunology, Immunotherapy, 2007
- ERAAP Synergizes with MHC Class I Molecules to Make the Final Cut in the Antigenic Peptide Precursors in the Endoplasmic ReticulumImmunity, 2006
- Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptidesin vivoand plays an important role in immunodominanceProceedings of the National Academy of Sciences of the United States of America, 2006